Qiagen QiAcuity dPCR PanCancer Kits and QiaSeq Targeted RNA-seq Panel for T-Cell Receptors

Qiagen has launched its QiAcuity dPCR PanCancer Kits and QiaSeq Targeted RNA-seq Panel for T-Cell Receptors.

QiAcuity dPCR PanCancer Kits use the company's QiAcuity digital PCR system to simultaneously detect multiple EGFR and BRAF hallmark mutations with high sensitivity. Researchers can use the kits to pre-screen samples before analyzing them with next-generation sequencing (NGS), for example, or for monitoring cancer cells, Qiagen said. The technology has the potential to be adapted to identify other genes associated with cancer risk, Qiagen added.

The new QiaSeq Targeted RNA-seq Panel for T-cell receptors uses unique molecular indices with QiaSeq enrichment technology to facilitate ultrasensitive and accurate characterization of the immune repertoire in humans and mice from low-input and FFPE samples. It enables targeted NGS detection of the following human or mouse expressed T-cell receptors: TCR-alpha, TCR-beta, TCR-gamma, and TCR-delta. This library prep kit is designed to accelerate research into areas such as how the T-cell receptor repertoire in cancer can be used as a biomarker and how the repertoire of tumor-infiltrating T cells can improve the understanding of tumor behavior, Qiagen said.